Merck v. Hikma: Sugammadex Patent Dispute Resolved via Res Judicata in Landmark ANDA Case
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Merck Sharp & Dohme v. Hikma Pharmaceuticals USA, Inc. |
| Case Number | 2:24-cv-03206 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | Mar 2024 – Sep 2025 1 year 6 months |
| Outcome | Plaintiff Win – Res Judicata Applied |
| Patents at Issue | |
| Accused Products | Hikma’s 2mg/200 mL generic version of Bridion® (sugammadex injection) |
Case Overview
The Parties
⚖️ Plaintiff
Global pharmaceutical leader and innovator of Bridion® (sugammadex), protecting its franchise through robust patent enforcement.
🛡️ Defendant
Multinational generic and specialty pharmaceutical manufacturer, seeking FDA approval for a generic sugammadex injection.
Patents at Issue
This landmark pharmaceutical case involved two patents anchoring the Bridion® franchise:
- • US RE44,733 — (Application No. 13/432,742) – covering core aspects of sugammadex technology.
- • US 6,670,340 B1 — (Application No. 10/148,307) – protecting the sugammadex compound or related pharmaceutical compositions.
Developing a similar drug formulation?
Check if your compound or formulation might infringe these or related patents.
The Verdict & Legal Analysis
Outcome
The District Court entered a Modified Final Judgment mirroring the resolution from the Consolidated Action, binding both parties to the Federal Circuit’s prior ruling. No separate damages award was assessed in this action. Notably, the court ordered that each party shall bear its own fees and costs.
Key Legal Issues
The legal engine driving this closure was the doctrine of res judicata (claim preclusion), which bars relitigation of claims already decided between the same parties or their privies. The Federal Circuit had previously ruled on the expiration date of U.S. Reissue Patent RE44,733 in the consolidated proceeding — a determination with direct downstream consequences for Hikma’s market entry timeline.
Filing a pharmaceutical patent?
Learn from this case. Use AI to draft stronger claims that can withstand litigation.
Power Your Pharma Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the pharmaceutical patent landscape with confidence.
⚠️ FTO Analysis for Pharmaceutical Innovations
This case highlights critical IP risks in pharmaceutical compounds and formulations. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this pharmaceutical litigation.
- View all related patents in the sugammadex technology space
- See which companies are most active in drug compound patents
- Understand claim construction patterns for reissue patents
🔍 Check My Drug Product’s Risk
Run a comprehensive FTO analysis for your own drug compound or formulation.
- Input your drug compound structure or formulation details
- AI identifies potentially blocking pharmaceutical patents
- Get actionable risk assessment report
High Risk Area
Sugammadex and related cyclodextrin compounds
2 Patents Involved
Reissue and foundational compound patents
Litigation Strategy Insights
Consolidation and res judicata lessons
✅ Key Takeaways
For Patent Attorneys
Res judicata from Federal Circuit-affirmed judgments in consolidated Hatch-Waxman actions binds parties in subsequent related district court proceedings.
Search related case law →Reissue patent expiration dates can be a decisive litigation variable — not merely administrative detail.
Explore precedents →For R&D Teams
Sugammadex-related compound development faces a protected IP landscape reinforced at the appellate level — conduct thorough FTO analysis before advancing similar cyclodextrin-based formulations.
Start FTO analysis for my drug →Track the expiration timeline of both RE44,733 and U.S. 6,670,340 B1 for generic entry planning.
Try AI patent drafting →Ready to Strengthen Your Pharma Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes in the pharmaceutical sector.